Financials
Financial year 2024
BRAEMS PHARMA CONSULTING from Villers-la-Ville, company number BE0719866791, closed financial year 2024 with a result of € 55,058 after tax. For that financial year BRAEMS PHARMA CONSULTING recorded a gross margin of € 79,228 and equity of € 192,542. Compared with financial year 2023, the result moved from € 52,220 to € 55,058. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 14, 2025.
€ 192,542
▲ 40% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 55,058
▲ 5% vs 2023
Profit after tax over the fiscal year.
€ 220,687
▲ 26% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € 192,442.
People and assets in 2024
€ 4,040
▲ € 3,434 vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 1,463
▲ 67% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 52,015
▲ 3% vs 2023
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 80,974 | € 81,338 | € 75,433 | € 79,228 | ▲ 5% |
| Profit after taxes | € 65,872 | € 62,232 | € 52,220 | € 55,058 | ▲ 5% |
| Equity | € 123,032 | € 85,264 | € 137,484 | € 192,542 | ▲ 40% |
| Total debts | € 45,685 | € 141,463 | € 51,521 | € 53,490 | ▲ 4% |
| Cash | € 158,533 | € 210,118 | € 175,084 | € 220,687 | ▲ 26% |
| Retained profit | € 122,932 | € 85,164 | € 137,384 | € 192,442 | ▲ 40% |
| Dividend | € 13,000 | € 100,000 | € 0 | € 0 | |
| Balance sheet total | € 168,717 | € 226,727 | € 189,005 | € 246,032 | ▲ 30% |
Key figures of BRAEMS PHARMA CONSULTING, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to BRAEMS PHARMA CONSULTING?
What happened at BRAEMS PHARMA CONSULTING in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 55,058 (▲ 5% vs 2023). filed late Source: NBB ↗
- New establishment in Villers-la-Ville. KBO
- Thérèse BRAEMS became a director. NBB
- Michel WAGNEUR became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 65,872 profit in 2021 to € 55,058 profit in 2024.
Paid € 76,078 in corporate taxes since 2021.
Best year ever: 2021, with € 65,872 profit.
Paid out € 113,000 in dividends to the owners in total.
A new publication or filing at BRAEMS PHARMA CONSULTING? We notify you, reason included.
Follow BRAEMS PHARMA CONSULTINGDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind BRAEMS PHARMA CONSULTING are Thérèse BRAEMS and Michel WAGNEUR.
Directors
According to the 2024 annual accounts
Thérèse BRAEMS
Director
since 2019
Michel WAGNEUR
Associate
since 2019
Establishments
Establishment units
Physical locations of this company
Rue du Try 16
1495 Villers-la-Ville
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0719.866.791
- VAT number
- BE 0719.866.791
- Registered office
- Rue du Try 16, 1495 Villers-la-Ville
- Names & denominations
- BRAEMS PHARMA CONSULTING
- Enterprise type
- Rechtspersoon
- Legal form
- Limited partnership
- Legal situation
- Normale toestand
- Start date
- 6 February 2019
- Peppol
- Active · Active since 23 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering